PND-1186 (VS-4718) 1061353-68-1
Product Description
.cp_wz table {border-top: 1px solid #ccc;border-left:1px solid #ccc; } .cp_wz table td{border-right: 1px solid #ccc; border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;} .cp_wz table th {border-right: 1px solid #ccc;border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;}
Molecular Weight:
501.5 PND-1186 (VS-4718) is a reversible and selective FAK Inhibitor with IC50 of 1.5 nM. Phase 1.
Biological Activity
In vitro, PND-1186 inhibits 4T1 breast carcinoma motility, promotes 4T1
Apoptosis in suspended conditions, and decreases 4T1 soft agar colony
number and size. In HEY and OVCAR8 cells, VS-4718 promotes G0-G1
cell-cycle arrest followed by cell death.
In mice bearing 4T1 tumors, PND-1186 (100 mg/kg s.c.) inhibits 4T1
subcutaneous tumor growth by induction of apoptosis. In mice bearing ID8
tumors, PND-1186 (0.5 mg/mL for p.o.) also causes ovarian carcinoma
tumor growth inhibition.
Protocol(Only for Reference)
Kinase Assay: [1]
Cell Assay: [1]
Animal Study: [1]
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
Chemical Information
Molarity Calculator
Dilution Calculator
Molecular Weight Calculator
Contact us if you need more details on 1061353-68-1. We are ready to answer your questions on packaging, logistics, certification or any other aspects about PND-1186 1061353-68-1、VS-4718 1061353-68-1. If these products fail to match your need, please contact us and we would like to provide relevant information.
Molecular Weight:
501.5 PND-1186 (VS-4718) is a reversible and selective FAK Inhibitor with IC50 of 1.5 nM. Phase 1.
Biological Activity
In vitro, PND-1186 inhibits 4T1 breast carcinoma motility, promotes 4T1
Apoptosis in suspended conditions, and decreases 4T1 soft agar colony
number and size. In HEY and OVCAR8 cells, VS-4718 promotes G0-G1
cell-cycle arrest followed by cell death.
In mice bearing 4T1 tumors, PND-1186 (100 mg/kg s.c.) inhibits 4T1
subcutaneous tumor growth by induction of apoptosis. In mice bearing ID8
tumors, PND-1186 (0.5 mg/mL for p.o.) also causes ovarian carcinoma
tumor growth inhibition.
Protocol(Only for Reference)
Kinase Assay: [1]
In vitro kinase activity | GST-FAK in vitro kinase activity is measured and compared to His-tagged FAK 411–686 using the K-LISA screening kit and poly(Glu:Tyr) (4:1) copolymer as a substrate immobilized on microtiter plates. IC50 values are determined with various concentrations of test compounds in a buffer containing 50 µM ATP and 10 mM MnCl2, 50 mM HEPES (pH 7.5), 25 mM NaCl, 0.01% BSA, and 0.1 mM Na orthovanadate for 5 min at room temperature. Serial diluted compounds are tested in triplicate. Substrate phosphorylation is measured using horseradish peroxidase-conjugated anti-pTyr antibodies with spetrophometic color quantitation. IC50 values are determined using the Hill-Slope Model. Kinase selectivity profiling is performed by using the KinaseProfiler service. |
---|
Cell Assay: [1]
Cell lines | Murine ID8 ovarian carcinoma cells |
---|---|
Concentrations | ~1 μM |
Incubation Time | 6 days |
Method | For soft agar assays, 48-well plates are coated with a 1:4 mix of 2% agar (EM Science) in 0.2 mL growth media (bottom layer). 5?04 cells are plated per well (in triplicate) in a mixture of 0.3% agar in 0.2 mL growth media (top layer). After agar solidification, 0.2 mL growth media is added containing DMSO or PND-1186 (final concentration for 0.6 mL). In separate experiments, PND-1186 is added after 4 days. After 10 days, colonies are imaged in phase contrast, enumerated by counting 9 fields (3 fields per well), and total area determined using Image J. For all analyses, experimental points are performed in triplicate and repeated at least two times. |
Animal Study: [1]
Animal Models | Mice bearing ID8 tumors or 4T1 tumors |
---|---|
Formulation | polyethylene glycol 400 (PEG400) in PBS (1:1) for s.c.; 5% sucrose for p.o. |
Dosages | 100 mg/kg every 12 hours for s.c.; 0.5 mg/mL for p.o. |
Administration | s.c. or p.o. |
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species | Baboon | Dog | Monkey | Rabbit | Guinea pig | Rat | Hamster | Mouse |
Weight (kg) | 12 | 10 | 3 | 1.8 | 0.4 | 0.15 | 0.08 | 0.02 |
Body Surface Area (m2) | 0.6 | 0.5 | 0.24 | 0.15 | 0.05 | 0.025 | 0.02 | 0.007 |
Km factor | 20 | 20 | 12 | 12 | 8 | 6 | 5 | 3 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
Rat dose (mg/kg) = mouse dose (22.4 mg/kg) × | mouse Km(3) | = 11.2 mg/kg |
rat Km(6) |
Chemical Information
Molecular Weight (MW) | 501.5 |
---|---|
Formula | C25H26F3N5O3 |
CAS No. | 1061353-68-1 |
Storage | 3 years -20℃Powder |
---|---|
6 months-80℃in solvent (DMSO, water, etc.) | |
Synonyms | SR-2156 |
Chemical Name | 2-(2-(2-methoxy-4-morpholinophenylamino)-5-(trifluoromethyl)pyridin-4-ylamino)-N-methylbenzamide |
---|
Molarity Calculator
Dilution Calculator
Molecular Weight Calculator
Contact us if you need more details on 1061353-68-1. We are ready to answer your questions on packaging, logistics, certification or any other aspects about PND-1186 1061353-68-1、VS-4718 1061353-68-1. If these products fail to match your need, please contact us and we would like to provide relevant information.
Product Categories : Angiogenesis > FAK Inhibitor
Other Products
Hot Products
Astragaloside AChlortetracycline HCl 64-72-2Paclitaxel 33069-62-4Dexamethasone Acetate 1177-87-3Dinaciclib (SCH727965) 779353-01-4CHIR-124 405168-58-3Ro3280 1062243-51-9TAME 901-47-3CCG-1423 285986-88-110058-F4 403811-55-2Dabigatran (BIBR 953) 211914-51-1H 89 2HCl 130964-39-5T0901317 293754-55-9Aprepitant 170729-80-3Turofexorate Isopropyl (XL335) 629664-81-9BMS-378806 357263-13-9